Introduction: When to Seek Diagnostic Testing

If you have been diagnosed with transitional cell carcinoma of the bladder, kidney, or ureter, your healthcare team will need to determine whether the cancer has spread beyond its original location. This process is known as staging, and it involves several tests to look for cancer in other parts of your body. You should undergo these diagnostic tests when you first receive a cancer diagnosis, or if you experience new symptoms after treatment has already begun.^[1]

People who notice symptoms such as unexplained weight loss, persistent pain in areas like the shoulder or back, lumps or masses in unusual places, or worsening fatigue should alert their doctor immediately. These can be signs that cancer has spread to distant sites. In some cases, metastatic disease is discovered at the same time as the original cancer diagnosis—this is called de novo metastatic disease. Other times, cancer spreads after initial treatment for a tumor that was thought to be confined to the bladder or kidney.^[2]

Approximately 10 to 15 percent of patients are diagnosed with metastatic bladder cancer at the time they first seek medical care. This means that the cancer had already traveled to other organs before any treatment could begin. Understanding whether your cancer has metastasized is essential because it changes the approach to treatment and helps doctors estimate your prognosis.^[23]

Diagnostic Methods for Metastatic Transitional Cell Carcinoma

Initial Evaluation and Physical Examination

The diagnostic process typically begins with a thorough physical examination by your doctor. During this exam, your healthcare provider will check for signs of cancer spread by feeling for enlarged lymph nodes, examining your abdomen for masses, and listening to your lungs. They will also ask detailed questions about your symptoms, including when they started, how severe they are, and whether they have changed over time.^[3]

Your doctor will review your medical history, paying special attention to any previous cancer diagnoses, treatments you have received, and risk factors such as smoking or exposure to certain chemicals. This information helps guide which diagnostic tests will be most useful for your specific situation.^[1]

Laboratory Tests

Blood and urine tests are fundamental tools in diagnosing and monitoring metastatic transitional cell carcinoma. A urinalysis examines your urine for the presence of blood, cancer cells, or other abnormalities. Blood in the urine, called hematuria, is often one of the first signs of cancer in the urinary system, though it can also be caused by other conditions.^[3]

Blood tests help assess your overall health and organ function. Your doctor will check your kidney function, liver enzymes, and blood cell counts. These tests can reveal whether cancer has affected organs like the liver or whether kidney function has been compromised. Blood tests also help determine if you are healthy enough to tolerate certain treatments, such as chemotherapy.^[1]

In some cases, doctors may look for cancer cells in urine samples by sending them to a laboratory where specialists examine them under a microscope. This test, called urine cytology, can help identify abnormal cells that suggest cancer is present or has spread.^[4]

Imaging Tests

Imaging tests are the primary way doctors determine whether cancer has spread to distant parts of the body. These tests create detailed pictures of the inside of your body, allowing healthcare providers to see tumors, enlarged lymph nodes, or other abnormalities.^[3]

A computed tomography (CT) scan uses X-rays and computer technology to produce cross-sectional images of your body. For metastatic transitional cell carcinoma, doctors often order CT scans of the chest, abdomen, and pelvis to check for cancer in the lungs, liver, lymph nodes, and other organs. CT scans are particularly useful because they can detect even small tumors and show whether cancer has invaded nearby tissues.^[3]

A specialized CT scan called a CT urogram uses a contrast dye injected into your veins to highlight the urinary system. This test is especially helpful for seeing blockages or tumors in the kidneys, ureters, and bladder. The contrast dye makes these structures stand out clearly on the scan, allowing doctors to identify abnormal areas.^[4]

Magnetic resonance imaging (MRI) uses powerful magnets and radio waves to create detailed images of soft tissues. MRI scans are particularly useful for examining the brain, spinal cord, and soft tissue masses. If there is concern that cancer has spread to these areas, an MRI may be ordered. In one documented case, a patient with metastatic transitional cell carcinoma had MRI scans that revealed soft tissue masses in the shoulder area, which turned out to be cancer that had spread from the bladder.^[2]

Bone scans help detect whether cancer has spread to the bones. During this test, a small amount of radioactive material is injected into your vein. The material collects in areas of bone where cancer is present, and a special camera takes pictures that show these spots as darker areas. Bone scans are important because bone metastases can cause pain and other complications.^[2]

Positron emission tomography (PET) scans use a radioactive sugar solution that cancer cells absorb more readily than normal cells. A special camera then detects where this sugar has accumulated, revealing areas of active cancer throughout the body. PET scans are sometimes combined with CT scans (PET-CT) to provide both functional and anatomical information about tumors.^[3]

Chest X-rays are a simpler imaging test that can detect large tumors or fluid in the lungs. While not as detailed as CT scans, chest X-rays are quick and inexpensive, making them useful for initial screening.^[1]

Tissue Sampling and Biopsy Procedures

When imaging tests reveal suspicious areas that might be cancer, doctors often need to obtain a tissue sample to confirm the diagnosis. This process is called a biopsy. A pathologist then examines the tissue under a microscope to determine whether cancer cells are present and what type they are.^[2]

For suspected metastatic lesions, doctors may perform a fine-needle aspiration, which uses a thin needle to remove a small amount of tissue from the suspicious area. This procedure is often guided by imaging techniques like ultrasound or CT to ensure the needle reaches the right spot. Fine-needle aspiration is less invasive than other biopsy methods and can usually be done in an outpatient setting. In one case, a fine-needle aspiration of a shoulder mass confirmed that it contained metastatic transitional cell carcinoma.^[2]

When examining the original tumor site or nearby areas, doctors may use cystoscopy to look inside the bladder or ureteroscopy to examine the ureter and kidney. During these procedures, a thin tube with a light and camera is inserted through the urethra. The doctor can see the inside of these organs directly and may take tissue samples for biopsy. However, these procedures have limitations when trying to determine how deeply cancer has invaded the tissue—a crucial factor in understanding the cancer’s stage.^[6]

Additional Diagnostic Considerations

Doctors sometimes order additional tests based on specific symptoms or findings. For example, if you are experiencing neurological symptoms such as headaches or confusion, a brain MRI or CT scan may be necessary to check for brain metastases. If you have respiratory symptoms, a chest CT can provide detailed images of the lungs.^[2]

Some specialized tests look at the characteristics of cancer cells themselves. For instance, doctors may test tumor tissue for specific genetic mutations or protein markers that can guide treatment decisions. One such marker is p53, a protein that can be found in high levels in some aggressive cancers. Testing for p53 and other markers helps doctors understand how aggressive the cancer is and may influence treatment choices.^[2]

Diagnostics for Clinical Trial Qualification

If you are considering participating in a clinical trial for metastatic transitional cell carcinoma, you will need to undergo specific diagnostic tests to determine if you qualify. Clinical trials have strict eligibility criteria that define which patients can enroll, and these criteria are based on factors such as the stage and characteristics of your cancer, your overall health, and previous treatments you have received.^[13]

Standard Staging and Assessment

Most clinical trials require complete staging information to ensure that participants have the specific type and stage of cancer being studied. This typically involves the full range of imaging tests described earlier, including CT scans of the chest, abdomen, and pelvis, as well as bone scans if bone metastases are suspected. These tests establish a baseline that researchers can use to measure whether the experimental treatment is working.^[1]

Doctors will also assess your performance status, which is a measure of how well you can carry out daily activities. Performance status helps predict how well you might tolerate treatment and is an important factor in determining clinical trial eligibility. Common scales used include the ECOG (Eastern Cooperative Oncology Group) performance status, which ranges from 0 (fully active) to 4 (completely disabled).^[13]

Laboratory Requirements

Clinical trials typically require specific blood and urine tests to ensure your organs are functioning well enough to handle the experimental treatment. These tests usually include a complete blood count, kidney function tests, and liver function tests. Some trials have specific cutoff values—for example, your kidney function must be above a certain level to receive drugs that are cleared through the kidneys.^[14]

In some cases, trials may require tests for specific biomarkers or genetic mutations in your tumor. For example, trials testing drugs that target fibroblast growth factor receptor (FGFR) alterations require proof that your tumor has these specific genetic changes. This involves specialized testing of tumor tissue obtained through biopsy.^[13]

Tissue and Biomarker Testing

Many modern clinical trials, especially those testing targeted therapies or immunotherapies, require fresh or archived tumor tissue for analysis. Researchers use this tissue to study the biological characteristics of your cancer and to determine if it has features that make it likely to respond to the experimental treatment. You may need to undergo a new biopsy if sufficient tissue from previous biopsies is not available.^[13]

Some trials test for immune system markers to predict whether you might benefit from immunotherapy drugs. Others look for specific proteins or genes that are targets of the experimental medication. The specific tests required vary depending on the trial, and your doctor will explain which tests are necessary for the studies you are considering.^[13]

Previous Treatment History

Clinical trials often specify what types of previous treatments you must have received—or must not have received—to be eligible. For example, some trials are specifically for patients who have already tried chemotherapy, while others are for patients who have not yet received any treatment. You will need documentation of all your previous treatments, including dates, drugs used, and how your cancer responded.^[13]

Trials may also require a certain amount of time to have passed since your last treatment before you can enroll. This washout period ensures that any effects from previous treatments have cleared from your system before starting the experimental therapy.^[14]